Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Goldenberg

Showing results (341-350 of 380) with videos related to

Pageof 38
Sort By:
Orphanet Journal of Rare Diseases|March 4, 2022
SATB2-associated syndrome: characterization of skeletal features and of bone fragility in a prospective cohort of 19 patientsM Mouillé, M Rio, S Breton, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
The Journal of Pediatrics|December 25, 2012
Arteriopathy, D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic strokeNeil A Goldenberg, Sarah Jenkins, Jessica Jack, et al.
Pediatrics|April 29, 2022
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 TrialAnthony A Sochet, John M Morrison, Julie Jaffray, et al.
Journal of Thrombosis and Haemostasis : JTH|June 30, 2015
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findingsN A Goldenberg, T Abshire, P J Blatchford, et al.
Human Genetics|October 7, 2018
Implication of non-coding PAX6 mutations in aniridiaJulie Plaisancié, M Tarilonte, P Ramos, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|August 18, 2021
A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis ConsortiumJulie Jaffray, Arash Mahajerin, Brian Branchford, et al.
Chembiochem : a European Journal of Chemical Biology|March 5, 2025
Donor-Acceptor (Perylenethienyl)Ethylenes as Singlet Oxygen-Photogenerating Viral InhibitorsMaxim S Krasilnikov, Roman V Mazur, Stepan P Chumakov, et al.
Neuromuscular Disorders : NMD|July 6, 2011
Intragenic rearrangements in LARGE and POMGNT1 genes in severe dystroglycanopathiesS Vuillaumier-Barrot, C Bouchet-Seraphin, M Chelbi, et al.
JAMA|January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical TrialNeil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
Pageof 38

Showing results (341-350 of 380) with videos related to

Sort By:
Pageof 38
Orphanet Journal of Rare Diseases|March 4, 2022
SATB2-associated syndrome: characterization of skeletal features and of bone fragility in a prospective cohort of 19 patientsM Mouillé, M Rio, S Breton, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
The Journal of Pediatrics|December 25, 2012
Arteriopathy, D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic strokeNeil A Goldenberg, Sarah Jenkins, Jessica Jack, et al.
Pediatrics|April 29, 2022
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 TrialAnthony A Sochet, John M Morrison, Julie Jaffray, et al.
Journal of Thrombosis and Haemostasis : JTH|June 30, 2015
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findingsN A Goldenberg, T Abshire, P J Blatchford, et al.
Human Genetics|October 7, 2018
Implication of non-coding PAX6 mutations in aniridiaJulie Plaisancié, M Tarilonte, P Ramos, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|August 18, 2021
A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis ConsortiumJulie Jaffray, Arash Mahajerin, Brian Branchford, et al.
Chembiochem : a European Journal of Chemical Biology|March 5, 2025
Donor-Acceptor (Perylenethienyl)Ethylenes as Singlet Oxygen-Photogenerating Viral InhibitorsMaxim S Krasilnikov, Roman V Mazur, Stepan P Chumakov, et al.
Neuromuscular Disorders : NMD|July 6, 2011
Intragenic rearrangements in LARGE and POMGNT1 genes in severe dystroglycanopathiesS Vuillaumier-Barrot, C Bouchet-Seraphin, M Chelbi, et al.
JAMA|January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical TrialNeil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
Pageof 38